← Back to Search

Procedure

RejuvenAir System for Chronic Bronchitis (SPRAY-CB Trial)

N/A
Waitlist Available
Led By Gerard Criner, MD
Research Sponsored by CSA Medical, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject demonstrates daily cough and significant mucus
Males and females ≥40 to ≤80 years of age
Must not have
Subject has had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 4 weeks prior of initially planned study bronchoscopy
Current diagnosis of Asthma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months

Summary

This trial is testing if a medicine can help people with CB.

Who is the study for?
This trial is for adults aged 40-80 with chronic bronchitis or COPD, who have had symptoms like daily cough and mucus for at least two years. They must not smoke, be able to use an eDiary, and agree to maintain their current lung medications. People can't join if they vape, had a recent lung infection, certain blood deficiencies or serious medical conditions, are pregnant, or have been in another study recently.
What is being tested?
The RejuvenAir System trial is testing a new procedure against a sham (fake) procedure to see if it helps people with chronic bronchitis within COPD. Participants will undergo bronchoscopy where the actual treatment or sham will be applied to compare effectiveness.
What are the potential side effects?
Potential side effects may include discomfort from the bronchoscopy procedure such as sore throat or coughing. There's also a risk of bleeding and infection from the intervention itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I cough daily and produce a lot of mucus.
Select...
I am between 40 and 80 years old.
Select...
I have been diagnosed with chronic bronchitis or COPD for at least two years.
Select...
I have moderate to severe lung obstruction based on my breathing test results.
Select...
I cough daily and produce a lot of mucus.
Select...
I have been following treatment for chronic bronchitis for at least 3 months and agree to continue my COPD medications during the study.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I've been treated for a lung infection or pneumonia with medication in the last 4 weeks.
Select...
I have been diagnosed with asthma.
Select...
My Alpha-1 antitrypsin levels are below 59 mg/dL.
Select...
My lung issues are not due to chronic bronchitis or COPD.
Select...
I use e-cigarettes, vape, or inhale substances not prescribed by a doctor.
Select...
I have severe heart rhythm problems or breathing issues that make certain lung procedures unsafe for me.
Select...
I have severe lung issues, such as large lung blisters or specific airway diseases.
Select...
I have a serious lung condition that affects my airways.
Select...
I have had an organ transplant.
Select...
I have had surgery on my lungs or have a known tear in the lining of my body cavities.
Select...
I have had a procedure done on my lungs, such as stents, coils, or other therapies.
Select...
I cannot stop taking my blood thinner medication temporarily.
Select...
I do not have any uncontrolled serious health conditions like heart failure or diabetes.
Select...
I am currently undergoing or have recently completed chemotherapy or radiation therapy.
Select...
I am allergic to medications used in lung exams.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
St. George's Respiratory Questionnaire
Secondary study objectives
Acute Exacerbation Rate (AECOPD)
Chronic Obstructive Airway Disease
Coughing
+2 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: TreatmentActive Control1 Intervention
RJA MCS
Group II: Sham ControlPlacebo Group1 Intervention
Sham

Find a Location

Who is running the clinical trial?

CSA Medical, Inc.Lead Sponsor
19 Previous Clinical Trials
743 Total Patients Enrolled
3 Trials studying Bronchitis
62 Patients Enrolled for Bronchitis
Gerard Criner, MDPrincipal InvestigatorTemple University Health System
9 Previous Clinical Trials
5,651 Total Patients Enrolled
1 Trials studying Bronchitis
2,981 Patients Enrolled for Bronchitis

Media Library

RejuvenAir System (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03893370 — N/A
Bronchitis Research Study Groups: Treatment, Sham Control
Bronchitis Clinical Trial 2023: RejuvenAir System Highlights & Side Effects. Trial Name: NCT03893370 — N/A
RejuvenAir System (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03893370 — N/A
~15 spots leftby May 2025